The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to provide an assessment of the change in baseline lipid parameters
with RVX000222 after 12 weeks and 24 weeks of treatment when given in addition to optimized
statin background therapy in subjects with low baseline HDL-C.